Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11004443 | 0.98 | TBXAS1 (0.61) | TBXAS1ALDH1A1ESR1CYP19A1NAPRT | |
| SCHEMBL7165228 | 0.91 | TBXAS1 (0.68) | TBXAS1ESR1CYP19A1NAPRTCHRNA7 | |
| SCHEMBL27939457 | 0.85 | TBXAS1 (0.64) | TBXAS1NAPRTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4657409 | 0.85 | ESR1 (0.59) | TBXAS1ESR1CYP19A1CHRNA7TDP1 | |
| SCHEMBL333061 | 0.83 | TBXAS1 (0.78) | TBXAS1NAPRTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29403620 | 0.83 | TBXAS1 (0.78) | TBXAS1NAPRTCYP1A2CYP3A4CYP2C9 | |
| Benzylacetone SCHEMBL27647678 | 0.82 | ALDH1A1 (0.62) | TBXAS1ALDH1A1NAPRTCYP1A2CYP3A4 | |
| SCHEMBL12530406 | 0.82 | TBXAS1 (0.57) | TBXAS1ESR1CYP19A1NAPRTCYP1A2 | |
| SCHEMBL1283208 | 0.81 | TBXAS1 (0.60) | TBXAS1ESR1CYP19A1NAPRTCYP1A2 | |
| SCHEMBL83186 | 0.81 | RECQL (0.62) | TBXAS1ESR1CYP19A1NAPRTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105523552-B | A kind of graphene composite conductive powder and preparation method thereof | 中国科学院宁波材料技术与工程研究所 | 2018-05-15 | — | — | CN | claimed |
| CN-105523552-A | Graphene compound conductive powder and preparation method thereof | NINGBO INST MAT TECH & ENG CAS | 2016-04-27 | — | — | CN | claimed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| EP-3490983-B1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| CN-105523552-B | A kind of graphene composite conductive powder and preparation method thereof | 中国科学院宁波材料技术与工程研究所 | 2018-05-15 | — | — | CN | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| US-9617309-B2 | Proline-locked stapled peptides and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-04-11 | — | — | US | disclosed |
| US-7465801-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
| EP-1521753-B1 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LTD (IN) | 2007-09-05 | — | — | EP | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1336612-B1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20060167061-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED | 2006-07-27 | — | — | US | disclosed |
| EP-1521753-A2 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LTD. (IN) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007490-A2 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LIMITED (IN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | TBXAS1 2807/4885ALDH1A1 968/4885ESR1 2144/4885 |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | TBXAS1 283/4885ALDH1A1 742/4885ESR1 2614/4885 |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | TBXAS1 320/4885ALDH1A1 1084/4885ESR1 2572/4885 |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | TBXAS1 1327/4885ALDH1A1 359/4885ESR1 894/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | TBXAS1 1011/4885ALDH1A1 4023/4885ESR1 3129/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | TBXAS1 1011/4885ALDH1A1 4023/4885ESR1 3129/4885 |
| US-20060167061-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | TBXAS1 320/4885ALDH1A1 1084/4885ESR1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.